RARECast

A podcast by RARECast - Thursdays

Thursdays

Categories:

512 Episodes

  1. The Psychological Toll Rare Diseases Can Have on Healthy Siblings

    Published: 5/29/2019
  2. Blood Test Can Provide Earlier Diagnosis of Autism Spectrum Disorder

    Published: 5/22/2019
  3. Understanding the Role of Natural History Studies in Clinical Trials

    Published: 5/15/2019
  4. How Two Mothers Discovered That a Drug for One Rare Disorder Might Benefit Another

    Published: 5/8/2019
  5. Shortening the Diagnostic Odyssey

    Published: 5/1/2019
  6. Eliminating Barriers to Adoption of Children with Rare Diseases

    Published: 4/24/2019
  7. A Young Rare Disease Advocate Discusses Life with an Undiagnosed Condition

    Published: 4/17/2019
  8. The Benefits of an Open-Source Registry for Rare Diseases

    Published: 4/10/2019
  9. How a Patient Group Helped Drive Drug Development in Rett Syndrome

    Published: 4/3/2019
  10. How Misperceptions Can Create Barriers to Care

    Published: 3/27/2019
  11. Targeting Repeat Expansion Disorders with Next-Gen Antisense Drugs

    Published: 3/21/2019
  12. Getting Misfolding Proteins to Shape Up

    Published: 3/13/2019
  13. A Different Approach to Inhibiting the Complement System

    Published: 3/6/2019
  14. Looking Back in Time to Find Rare Disease Patients Today

    Published: 2/27/2019
  15. Ionis CEO Stanley Crooke Discusses Success as a Platform Technology Company

    Published: 2/20/2019
  16. Orchard Looks toward Harvesting Expanded Gene Therapy Pipeline

    Published: 2/13/2019
  17. Connecting Rare Disease Patients in India and the United States

    Published: 2/6/2019
  18. Regenerative Medicine Moves into the Spotlight

    Published: 1/30/2019
  19. Learning New Tricks from Pathogenic Bacteria to Target the Microbiome

    Published: 1/24/2019
  20. Orphan Drug Accelerator Spin-Out Tackles Rare Endocrine Disorders

    Published: 1/16/2019

15 / 26

RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.